Oral Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

NCT06329063 | Recruiting

• 1 other identifier: BAM_lab_eyetracking_03
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

Conditions

Healthy

Keywords

Eye-tracking; vasopressin; looming fear

Outcome Measures

Primary Outcomes (1)

• Ratio of judged-time-to-collision to actual-time-to-collision for threatening versus non-threatening stimuli after oral vasopressin administration

  Comparison of the ratio between the judged time to collision and the actual time to collision between the treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.

  75 minutes - 105 minutes after treatment

Secondary Outcomes (2)

• First saccade latency(ms) for threatening versus non-threatening stimuli after oral vasopressin administration

  75 minutes - 105 minutes after treatment

• Fixation duration(ms) for threatening versus non-threatening stimuli after oral vasopressin administration

  75 minutes - 105 minutes after treatment

Study Arms (2)

Vasopressin group

EXPERIMENTAL

Drug: Vasopressin (20IU)

Drug: Vasopressin

Placebo group

PLACEBO COMPARATOR

Drug: Placebo

Drug: Placebo

Interventions

Vasopressin DRUG

Administration of vasopressin (20 IU) (oral spray)

Also known as: Antidiuretic Hormone

Vasopressin group

Placebo DRUG

Administration of placebo (oral spray)

Also known as: Placebo treatment

Placebo group

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.
• Normal or corrected-normal version

You may not qualify if:

• History of neuropsychiatric diseases.
• History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
• History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
• History of renal diseases, including renal stones or renal failure.
• History of hyponatremia(Serum sodium \<135mmol/L) or hyperkalemia (Serum potassium\>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
• Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
• Infections such as COVID-19 or influenza, or unexplained fever.
• Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
• History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.

Sponsors & Collaborators

• University of Electronic Science and Technology of China: lead

Study Sites (1)

University of Electronic Science and Technology of China

Chengdu, Sichuan, China

RECRUITING

MeSH Terms

Conditions

Diabetes Insipidus

Interventions

Vasopressins

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Pituitary Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Pituitary Hormones, Posterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Oligopeptides; Nerve Tissue Proteins; Proteins

Study Officials

• Benjamin Becker, Dr

  University of Electronic Science and Technology of China

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Weihua Zhao, Dr

CONTACT

86-28-61830811; zarazhao.uestc@outlook.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Randomized placebo-controlled double-blind between-subject design
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 15, 2024
• First Posted: March 25, 2024
• Study Start: March 5, 2024
• Primary Completion: June 1, 2025
• Study Completion: July 30, 2025
• Last Updated: April 11, 2024

Record last verified: 2024-04

Locations

CN (1)